Lupus Nephritis Biomarkers Highlight Race-Based Differences
https://pixabay.com/en/hand-united-together-people-unity-1917895/

Lupus Nephritis Biomarkers Highlight Race-Based Differences

When studying biomarkers of lupus nephritis, researchers at the University of Houston discovered something interesting: race-based differences. Biomarkers are some sort of measurable substance; in this case, urinary proteins. However,…

Continue Reading Lupus Nephritis Biomarkers Highlight Race-Based Differences

AURORA Study Finds Voclosporin Effective for Lupus Nephritis Treatment

  According to an article in Healio, the immunosuppressing drug voclosporin was found to be effective in stimulating renal responses in patients with lupus nephritis. About Lupus Nephritis Lupus nephritis…

Continue Reading AURORA Study Finds Voclosporin Effective for Lupus Nephritis Treatment

Pediatric Cancer and the 70th Anniversary of the Leukemia & Lymphoma Society

  When the Leukemia & Lymphoma Society (LLS) was founded in 1949 by a family in memory of their sixteen-year-old son, cancer was considered a hopeless condition. As noted recently…

Continue Reading Pediatric Cancer and the 70th Anniversary of the Leukemia & Lymphoma Society
Lupus Nephritis Patients Should be Excited About the Results of This Phase 3 Trial
source: pixabay.com

Lupus Nephritis Patients Should be Excited About the Results of This Phase 3 Trial

According to a story from BioPortfolio, the biopharmaceutical company Aurinia Pharmaceuticals, Inc. has recently announced positive findings from its phase 3 clinical trial of the experimental drug voclosporin, which was…

Continue Reading Lupus Nephritis Patients Should be Excited About the Results of This Phase 3 Trial

Failure of Promising Investigatory Lupus Drug Prompts Discussion to Improve Clinical Trials

According to a publication from The Rheumatologist, the recent failure of a seemingly-promising lupus treatment in a phase 2 study has led to a discipline-wide discussion about new research and…

Continue Reading Failure of Promising Investigatory Lupus Drug Prompts Discussion to Improve Clinical Trials
Ongoing Research Aims to Improve Monitoring and Detection for Lupus Nephritis
FotoshopTofs / Pixabay

Ongoing Research Aims to Improve Monitoring and Detection for Lupus Nephritis

According to a story from news-medical.net, a pair of researchers affiliated with the University of Houston are planning to dedicate their time to improving detection and monitoring of lupus nephritis,…

Continue Reading Ongoing Research Aims to Improve Monitoring and Detection for Lupus Nephritis

New Potential Treatment for Systemic-Onset Juvenile Idiopathic Arthritis Investigated in China

SOJIA SOJIA stands for systemic-onset Juvenile Idiopathic Arthritis (JIV). It is a very severe form of JIA which causes joint pain, inflammation, recurrent fevers, and a skin rash. Patients often take predinsolone,…

Continue Reading New Potential Treatment for Systemic-Onset Juvenile Idiopathic Arthritis Investigated in China

Phase 1b Trial for Lupus Nephritis Utilizing New Therapeutic Approach to Commence Soon

Lupus Nephritis Lupus nephritis (LN) is one of the most common complications of systemic lupus erythematosus (SLE). It affects approximately 100,000 patients in the United States alone. Basically, the patient's…

Continue Reading Phase 1b Trial for Lupus Nephritis Utilizing New Therapeutic Approach to Commence Soon

Orphan Drug Designation Given for Potential New Treatment for C3 Globerulopathy

Apellis Pharmaceuticals has just announced that they have received Orphan Drug Designation from the FDA for APL-2, a C3 complement inhibitor. The company is currently investigating the drug as a…

Continue Reading Orphan Drug Designation Given for Potential New Treatment for C3 Globerulopathy
Clinical Trials Underway for Potential Lupus Nephritis and FSGS Treatment
Source: Pixabay

Clinical Trials Underway for Potential Lupus Nephritis and FSGS Treatment

According to Business Wire, a pharmaceutical company, Aurinia Pharmaceuticals Inc., recently announced that they have enrolled the first lupus nephritis patients in the AURORA 2 extension study. Not only this, but Aurinia…

Continue Reading Clinical Trials Underway for Potential Lupus Nephritis and FSGS Treatment
Clinical Trials Underway for Potential Lupus Nephritis and FSGS Treatment
Source: Pixabay

Clinical Trials Underway for Potential Lupus Nephritis and FSGS Treatment

According to Business Wire, a pharmaceutical company, Aurinia Pharmaceuticals Inc., recently announced that they have enrolled the first lupus nephritis patients in the AURORA 2 extension study. Not only this, but Aurinia…

Continue Reading Clinical Trials Underway for Potential Lupus Nephritis and FSGS Treatment
What You Need to Know About This Autoimmune Breakthrough: RU.521
source: pixabay.com

What You Need to Know About This Autoimmune Breakthrough: RU.521

With original findings reported in Nature Communications, a newly tested compound, RU.521, may provide the key to understanding and combating autoimmune conditions such as Aicardi-Goutieres Syndrome, and Lupus. Cyclic GMP-AMP…

Continue Reading What You Need to Know About This Autoimmune Breakthrough: RU.521

Editor’s Choice: Soo Many Promising Results, Advancements and Treatment Options for the Rare Disease World!

TGIF Patient Worthians! This week we have promising results on promising results. First up is news on a Dravet syndrome treatment. Second is a Lupus Nephritis drug in the works! Third…

Continue Reading Editor’s Choice: Soo Many Promising Results, Advancements and Treatment Options for the Rare Disease World!
This New Drug Would Change Lupus Nephritis Treatment Forever
Source: https://pixabay.com/en/sky-clouds-rays-sun-hope-sunbeam-1107952/

This New Drug Would Change Lupus Nephritis Treatment Forever

In late May of this year, Aurinia Pharmaceuticals Inc. dosed its first patient with voclosporin in a Phase 3 trial known as AURORA. AURORA is a confirmatory clinical trial to…

Continue Reading This New Drug Would Change Lupus Nephritis Treatment Forever
Close Menu